Wishing everyone a Happy Thanksgiving as you reflect on what you are grateful for. #Thanksgiving2021 #GenEdit

From all of us at GenEdit, wishing you a happy holiday season.

Today, SRPT announced a research and option agreement with GenEdit Inc to develop #geneediting therapeutics for the treatment of #neuromuscular diseases. Learn more: bit.ly/3udwZXr

We're excited to announce our collaboration with Sarepta Therapeutics to develop new #geneticmedicines for neuromuscular diseases and the progress we have made together in using our #NanoGalaxy platform to target muscle for #geneediting. Read more: genedit.com/news/sarepta-t…

Our CEO and cofounder Kunwoo Lee spoke with Kyle LaHucik about how the Sarepta Therapeutics collaboration in neuromuscular conditions has been a great place to show how our #NanoGalaxy platform works for delivery of #genediting therapies. Read more on @fiercebiotech: fiercebiotech.com/biotech/sarept…

The GenEdit team is growing! We are looking for motivated individuals who wish to make an impact to join our team! To view a list of our openings: genedit.com/join-us/ #hiring #opportunities #startuphiring #Nanogalaxy

We are excited to welcome Barbara Leyman, Ph.D. as GenEdit’s Vice President of Business Development. Barbara brings extensive licensing and partnership experience to the GenEdit leadership team. Welcome Barbara!

Excited to have our CEO, Kunwoo Lee, share GenEdit's targeted, in vivo delivery platform technology with the WuXi AppTec interview series. View the full interview here: ow.ly/jKOu50JfExM

Delighted to announce that our CEO, Kunwoo Lee will present at the CRS 2022 Annual Meeting & Expo in Montreal, Canada on Thursday July 14th. Join this presentation to hear more about #GenEdit's promising #NanoGalaxy in vivo delivery platform technology.

1 of 2: Congratulations to Editas Medicine for the new status of RUBY as a Phase 1/2/3 trial! With the potential to revolutionize treatment for sickle cell anemia patients, Reni-cel represents a significant advancement in medical innovation.

2 of 2: Reni-cel represents a significant advancement in medical innovation. This milestone is also exciting for GenEdit because Reni-cel incorporates our cutting-edge technologies licensed to Editas.

GenEdit is growing! 🚀 We're moving from the Lilly Gateway Labs to a larger, cutting-edge space at Genesis-Marina in the South San Francisco biotech hub. Thanks, Eli Lilly! Onward & upward! #GenEdit #NewHQ #GenesisMarina #LifeSciences #SouthSanFrancisco #Biotech

GenEdit welcomes Dr. J. Rodrigo Mora as Chief Scientific Officer. With 25+ years of  R&D experience, Dr. Mora will advance our NanoGalaxy® platform and accelerate programs to develop novel therapeutics in neurology, immunology and immuno-oncology. genedit.com/news/genedit-a…

GenEdit welcomes Dong Kim, MBA, as Chief Business Officer and Jeff Kim, CPA, as CFO. Dong will advance our pipeline strategy of partnered and wholly-owned therapeutic candidates, while Jeff will lead financial efforts to support our continued growth. genedit.com/about/

Our CEO & Cofounder Kunwoo Lee will speak at #TIDESUSA next week, highlighting GenEdit’s NanoGalaxy® platform for tissue-specific RNA delivery and immune modulation. Session info: informaconnect.com/tides/speakers… Learn more: genedit.com/science/ #geneticmedicines #autoimmunedisease

We’re heading to #BIO2025! Our CEO & Cofounder Kunwoo Lee will present a company overview on June 17, 3pm ET. We will also be participating in 1x1 partnering. Connect with us to talk about NanoGalaxy® and RNA delivery. genedit.com/science/ #geneticmedicines #DrugDelivery

Excited to share that our South Korea research center is expanding and our global team is growing. As we advance the NanoGalaxy® platform for targeted RNA delivery, we're building the team infrastructure to realize the full potential of #geneticmedicines. genedit.com/science/

Congrats to Drs. Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi, winners of the 2025 #NobelPrize in Physiology or Medicine for discoveries in peripheral tolerance that continue to inspire GenEdit’s nanoparticle-based approaches to immune tolerance. nobelprize.org/prizes/medicin…

We’re heading to #BIOEurope! We will be participating in 1x1 partnering. Connect with us to talk about RNA delivery using GenEdit’s Nanogalaxy® proprietary nanoparticle technology platform. genedit.com/science/ #geneticmedicines #DrugDelivery